I'm an infectious disease pharmacist at a large teaching hospital, and we're seeing a troubling increase in cases of carbapenem-resistant Enterobacteriaceae in our ICU, limiting our treatment options and leading to worse patient outcomes. Our antimicrobial stewardship program is reviewing its protocols, but we need more aggressive strategies. For other healthcare professionals on the front lines of this fight, what infection control measures or treatment algorithms have you found most effective in containing outbreaks of highly resistant organisms? How are you navigating the use of newer, last-resort antibiotics to preserve their efficacy, and what role is rapid diagnostic testing playing in your institution's approach to antimicrobial resistance?
Solid topic. In practice, start with a robust infection-control baseline: contact precautions for CRE, single room or dedicated cohort, dedicated equipment, and strict hand hygiene with ongoing audits. Use a consistent cleaning protocol with an EPA-registered disinfectant. Consider targeted active surveillance for high-risk units or patients with known exposure. Minimize patient transfers; cohort staff if possible; ensure gloves and gown use, and reinforce with a quick, daily huddle to flag potential cases.
Treatment algorithms: base decisions on local susceptibility data and rapid diagnostics. Ceftazidime-avibactam covers many KPC and OXA-48 producers; meropenem-vaborbactam is a strong option for KPC; cefiderocol can be used for difficult-to-treat gram-negatives, including some resistant strains. For MBL producers, aztreonam-avibactam (often with a companion beta-lactam) is a consideration. Use last-line agents only after confirmation and in consultation with ID; avoid monotherapy when feasible, and prioritize de-escalation as soon as susceptibilities are known. Monitor renal function and potential nephrotoxicity or other adverse effects, especially with aminoglycosides or polymyxins.
Rapid diagnostics: invest in PCR-based carbapenemase gene panels (KPC, NDM, VIM, OXA-48) and rapid ID (MALDI-TOF) to cut days off decision timelines. Use results to accelerate isolation decisions and tailor therapy sooner, then confirm with culture. Integrate with the LIS and EMR so alerts trigger infection-control actions and stewardship reviews.
Stewardship structure: implement pre-authorization for certain last-line agents or post-prescription review within 24–48 hours. Develop local treatment guidelines anchored to susceptibility data, with a clear de-escalation path. Train frontline staff on when to order rapid tests and how to interpret results, and establish a stewardship-to-ICU liaison for high-risk cases.
Operational outcomes to track: time to isolation after admission/suspected infection, CRE bloodstream infection rates, incidence density, days of therapy per 1,000 patient-days, transition from broad to narrow therapy, nephrotoxicity rates, and costs. Use that data to refine protocols quarterly and share a transparent dashboard with leadership and frontline teams.
Pilot plan: propose a 3-month pilot in one ICU or high-risk ward to test rapid diagnostics, a streamlined isolation workflow, and a restrictive-use policy for last-line agents; if successful, scale hospital-wide with a governance structure, training plan, and staged rollout. If you want, tell me your facility size, existing diagnostics, and formulary so I can tailor a concrete action list and a governance model.